Skip to content

13F-HR filed by Casdin Capital, LLC

Casdin Capital, LLC filed this 13F-HR for the quarter ended 2018-06-30, filed 2018-08-14, with 35 holding rows worth $686,545,000.

Accession
0001172661-18-001605
Filed
2018-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2018

A holdings report, 35 entries on the cover page, a total value of $686,545,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $686,545,000 with VALUE read as thousands by filing date, 13F file number 028-17113. A later restatement replaced it, so the quarter does not use it. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
Foundation Medicine Inc350465100COM685,000$93,640,000thousands by filing date
LOXO ONCOLOGY INC548862101COM360,000$62,453,000thousands by filing date
BLUEPRINT MEDICINES CORP09627Y109COM635,000$40,310,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM250,000$39,133,000thousands by filing date
MYOKARDIA INC62857M105COM780,000$38,727,000thousands by filing date
SPARK THERAPEUTICS INC84652J103COM463,000$38,318,000thousands by filing date
BLUEBIRD BIO INC09609G100COM200,000$31,390,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM364,776$30,725,000thousands by filing date
FATE THERAPEUTICS INC31189P102COM2,600,000$29,484,000thousands by filing date
CODEXIS INC192005106COM2,025,000$29,160,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock270,000$26,592,000thousands by filing date
VOYAGER THERAPEUTICS INC92915B106COMMON STOCK1,135,000$22,178,000thousands by filing date
GLOBAL BLOOD THERAPEUTICS USD37890U108COM480,000$21,696,000thousands by filing date
GENMARK DIAGNOSTICS INC372309104COM3,400,000$21,692,000thousands by filing date
ILLUMINA INC452327109COM71,500$19,969,000thousands by filing date
SANGAMO THERAPEUTICS INC800677106COM1,400,000$19,880,000thousands by filing date
AUDENTES THERAPEUTICS INC.05070R104Common Stock450,000$17,195,000thousands by filing date
CRISPR THERAPEUTICS AG NAMEN AKTH17182108Stock220,000$12,927,000thousands by filing date
EVOLENT HEALTH INC CL A30050B101Stock550,000$11,578,000thousands by filing date
BEONE MEDICINES LTD SPONSORED ADS07725L102ADR70,000$10,761,000thousands by filing date
ORASURE TECHNOLOGIES INC68554V108COM640,000$10,541,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM220,000$10,003,000thousands by filing date
BIOLIFE SOLUTIONS INC COM NEW09062W204Stock1,000,000$8,332,000thousands by filing date
EDITAS MEDICINE INC28106W103COM178,333$6,390,000thousands by filing date
DIANTHUS THERAPEUTICS INC COM55910K108Stock400,000$5,400,000thousands by filing date
NEOGEN CORP640491106COM65,000$5,212,000thousands by filing date
CYTOMX THERAPEUTICS INC23284F105COMMON STOCK207,500$4,743,000thousands by filing date
LOXO ONCOLOGY INC548862101COM20,000$3,470,000thousands by filing dateput
ZAI LAB LTD ADR98887Q104ADR135,000$3,139,000thousands by filing date
JOUNCE THERAPEUTICS INC481116101COM375,000$2,873,000thousands by filing date
CAREDX INC14167L103COM200,000$2,448,000thousands by filing date
TRANSPORTATION & LOGISTI438083107COM115,000$2,346,000thousands by filing date
GLOBAL BLOOD THERAPEUTICS USD37890U108COM50,000$2,260,000thousands by filing dateput
NEON THERAPEUTICS INC64050Y100COM75,000$945,000thousands by filing date
BLUEPRINT MEDICINES CORP09627Y109COM10,000$635,000thousands by filing datecall

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001172661-18-001605this filing2018-08-14acceptance time not in the bulk data set
13F-HR/A 0001172661-18-001712 base2018-08-20acceptance time not in the bulk data set